1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
  5. > Systemic Juvenile Idiopathic Arthritis (SJIA) Global Clinical Trials Review, H2, 2015

Systemic Juvenile Idiopathic Arthritis (SJIA) Global Clinical Trials Review, H2, 2015

Summary

GlobalData's clinical trial report, “Systemic Juvenile Idiopathic Arthritis (SJIA) Global Clinical Trials Review, H2, 2015" provides an overview of Systemic Juvenile Idiopathic Arthritis (SJIA) clinical trials scenario. This report provides top line data relating to the clinical trials on Systemic Juvenile Idiopathic Arthritis (SJIA). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table Of Contents

Systemic Juvenile Idiopathic Arthritis (SJIA) Global Clinical Trials Review, H2, 2015
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Systemic Juvenile Idiopathic Arthritis (SJIA) to Musculoskeletal Clinical Trials 15
Clinical Trials by Phase in G7 Countries 17
Clinical Trials in G7 Countries by Trial Status 18
Clinical Trials by E7 Countries: Proportion of Systemic Juvenile Idiopathic Arthritis (SJIA) to Musculoskeletal Clinical Trials 19
Clinical Trials by Phase in E7 Countries 21
Clinical Trials in E7 Countries by Trial Status 22
Clinical Trials by Phase 23
In Progress Trials by Phase 24
Clinical Trials by Trial Status 25
Clinical Trials by End Point Status 26
Subjects Recruited Over a Period of Time 27
Clinical Trials by Sponsor Type 28
Prominent Sponsors 29
Top Companies Participating in Systemic Juvenile Idiopathic Arthritis (SJIA) Therapeutics Clinical Trials 31
Prominent Drugs 33
Clinical Trial Profile Snapshots 34
Appendix 64
Abbreviations 64
Definitions 64
Research Methodology 65
Secondary Research 65
About GlobalData 66
Contact Us 66
Disclaimer 66
Source 67

List of Tables
Systemic Juvenile Idiopathic Arthritis (SJIA) Therapeutics, Global, Clinical Trials by Region, 2015* 6
Systemic Juvenile Idiopathic Arthritis (SJIA) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 8
Systemic Juvenile Idiopathic Arthritis (SJIA) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 9
Systemic Juvenile Idiopathic Arthritis (SJIA) Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2015* 10
Systemic Juvenile Idiopathic Arthritis (SJIA) Therapeutics Clinical Trials, Europe, Top Five Countries, 2015* 11
Systemic Juvenile Idiopathic Arthritis (SJIA) Therapeutics Clinical Trials, North America, Top Countries, 2015* 12
Systemic Juvenile Idiopathic Arthritis (SJIA) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2015* 13
Systemic Juvenile Idiopathic Arthritis (SJIA) Therapeutics Clinical Trials, Central and South America, Top Countries, 2015* 14
Proportion of Systemic Juvenile Idiopathic Arthritis (SJIA) to Musculoskeletal Clinical Trials, G7 Countries (%), 2015* 16
Systemic Juvenile Idiopathic Arthritis (SJIA) Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 17
Systemic Juvenile Idiopathic Arthritis (SJIA) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 18
Proportion of Systemic Juvenile Idiopathic Arthritis (SJIA) to Musculoskeletal Clinical Trials, E7 Countries (%), 2015* 20
Systemic Juvenile Idiopathic Arthritis (SJIA) Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* 21
Systemic Juvenile Idiopathic Arthritis (SJIA) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015* 22
Systemic Juvenile Idiopathic Arthritis (SJIA) Therapeutics, Global, Clinical Trials by Phase, 2015* 23
Systemic Juvenile Idiopathic Arthritis (SJIA) Therapeutics, Global, Clinical Trials In Progress by Phase 2015* 24
Systemic Juvenile Idiopathic Arthritis (SJIA) Therapeutics, Global, Clinical Trials by Trial Status, 2015* 25
Systemic Juvenile Idiopathic Arthritis (SJIA) Therapeutics Clinical Trials, Global, by End Point Status, 2015* 26
Systemic Juvenile Idiopathic Arthritis (SJIA) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 27
Systemic Juvenile Idiopathic Arthritis (SJIA) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2015* 28
Systemic Juvenile Idiopathic Arthritis (SJIA) Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 30
Systemic Juvenile Idiopathic Arthritis (SJIA) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 32
Systemic Juvenile Idiopathic Arthritis (SJIA) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 33

List of Figures
Systemic Juvenile Idiopathic Arthritis (SJIA) Therapeutics, Global, Clinical Trials by Region (%), 2015* 6
Systemic Juvenile Idiopathic Arthritis (SJIA) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 7
Systemic Juvenile Idiopathic Arthritis (SJIA) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 9
Systemic Juvenile Idiopathic Arthritis (SJIA) Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2015* 10
Systemic Juvenile Idiopathic Arthritis (SJIA) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2015* 11
Systemic Juvenile Idiopathic Arthritis (SJIA) Therapeutics Clinical Trials, North America, Top Countries (%), 2015* 12
Systemic Juvenile Idiopathic Arthritis (SJIA) Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2015* 13
Systemic Juvenile Idiopathic Arthritis (SJIA) Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2015* 14
Proportion of Systemic Juvenile Idiopathic Arthritis (SJIA) to Musculoskeletal Clinical Trials, G7 Countries (%), 2015* 15
Systemic Juvenile Idiopathic Arthritis (SJIA) Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 17
Systemic Juvenile Idiopathic Arthritis (SJIA) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 18
Proportion of Systemic Juvenile Idiopathic Arthritis (SJIA) to Musculoskeletal Clinical Trials, E7 Countries (%), 2015* 19
Systemic Juvenile Idiopathic Arthritis (SJIA) Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* 21
Systemic Juvenile Idiopathic Arthritis (SJIA) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015* 22
Systemic Juvenile Idiopathic Arthritis (SJIA) Therapeutics, Global, Clinical Trials by Phase (%), 2015* 23
Systemic Juvenile Idiopathic Arthritis (SJIA) Therapeutics, Global, Clinical Trials In Progress by Phase, 2015* 24
Systemic Juvenile Idiopathic Arthritis (SJIA) Therapeutics, Global, Clinical Trials by Trial Status, 2015* 25
Systemic Juvenile Idiopathic Arthritis (SJIA) Therapeutics Clinical Trials, Global, by End Point Status, 2015* 26
Systemic Juvenile Idiopathic Arthritis (SJIA) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 27
Systemic Juvenile Idiopathic Arthritis (SJIA) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2015* 28
Systemic Juvenile Idiopathic Arthritis (SJIA) Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 29
Systemic Juvenile Idiopathic Arthritis (SJIA) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 31
Systemic Juvenile Idiopathic Arthritis (SJIA) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 33
GlobalData Methodology 65

Companies Mentioned
F. Hoffmann-La Roche Ltd.
Novartis AG
Ono Pharmaceutical Co., Ltd.
Johnson and Johnson
Italfarmaco S.p.A.
International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Horizon Pharma Plc
Bristol-Myers Squibb Company
Arthritis Research UK
Amgen Inc.

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Systemic Lupus Erythematosus Market: By Therapies (Antimalarial Drugs, Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids Cytotoxic & Immunosuppressive Drugs, Biologics, Small Molecules) & By Region (Asia-Pacific, Others)-Forecast (2016-2021)

Systemic Lupus Erythematosus Market: By Therapies (Antimalarial Drugs, Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids Cytotoxic & Immunosuppressive Drugs, Biologics, Small Molecules) & By Region (Asia-Pacific, Others)-Forecast (2016-2021)

  • $ 5250
  • Industry report
  • September 2016
  • by Industry ARC

Systemic lupus erythematosus, also commonly known as lupus, is an autoimmune disease which results in inflammation of tissues in the body with common symptoms like fever, fatigue, skin rashes, malaise, ...

Epiomic Epidemiology Series: Osteoarthritis Forecast in 9 Major Markets 2016-2026

Epiomic Epidemiology Series: Osteoarthritis Forecast in 9 Major Markets 2016-2026

  • $ 5112
  • Industry report
  • October 2016
  • by Black Swan Analysis Ltd132

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Osteoarthritis in 9 Major Markets Osteoarthritis (OA), also known as degenerative joint disease / degenerative arthritis, is an inflammation ...

Global Osteoporosis Drugs Market Size, Share, Development, Growth and Demand Forecast to 2022- Industry Insights by Drug Class

Global Osteoporosis Drugs Market Size, Share, Development, Growth and Demand Forecast to 2022- Industry Insights by Drug Class

  • $ 5100
  • Industry report
  • November 2016
  • by P&S Market Research

The global osteoporosis drugs market was worth $8,835.4 million in 2015 and it is expected to grow at a CAGR of 3.8% during 2016-2022. Among the various drug classes, the rank ligand inhibitors segment ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.